Please login to the form below

Not currently logged in
Email:
Password:

Teva fights off Novartis to market generic famciclovir tablets

Teva wins favourable ruling against Novartis for a preliminary injunction related to the Israeli firm's famciclovir treatment for genital herpes

Israeli-based Teva has received a favourable ruling from the US District Court for the District of New Jersey regarding a lawsuit filed by Swiss pharmaceutical company Novartis for a preliminary injunction related to Teva's famciclovir, a generic version of Novartis' Famvir treatment for genital herpes.

Teva's ANDA to market famciclovir tablets in 125 mg, 250 mg and 500 mg has already been granted final approval by the FDA.

Famvir had annual sales of approximately USD 200m in the US for the twelve months to 30 June 2007, based on IMS data. As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity, which will begin from the date of first commercial marketing.

Teva is currently involved in patent litigation with Novartis concerning this product. A trial date has yet to be set.

7th September 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

OPEN Health delivers over 250 virtual activities during COVID-19 – A clear path forward
...
Can eLearning improve patient recruitment and retention?
Some patients will still want to read pages of informed consent forms before joining a clinical trial, or want timely updates on paper rather than a notification on their phone....
How Far Do You Want To Go?
Join OPEN Health's virtual careers event on Tuesday 10th November, 15:00–17:00 GMT and discover where a career in medical communications could take you…...

Infographics